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Tubulointerstitial nephritis and uveitis
(TINU) syndrome: a systematic review of its
epidemiology, demographics and risk
factors
Linda O. Okafor1,2, Peter Hewins3,4, Philip I. Murray2,5 and Alastair K. Denniston1,4,5,6*
Abstract
Tubulointerstitial nephritis and uveitis (TINU) syndrome is a rare oculorenal inflammatory condition that was first
described in 1975. In 2001 a major review identified 133 cases in the world literature and proposed key diagnostic
criteria for the condition. Although acknowledged as rare, the limited data available prevented reliable estimates of
the prevalence of the condition, and hampered elucidation of the relationship between genetic and environmental
factors that contribute to its pathogenesis.
In this review we have performed a systematic search on the epidemiology, demographics and proposed risk factors for
TINU. Estimates of prevalence based on studies that explicitly report TINU cases suggest that it is diagnosed in 0.2–2% of
patients attending specialist uveitis services, with variation reflecting a number of factors including level of diagnostic
certainty required. The prevalence of uveitis in patients with tubulointerstitial nephritis (TIN) may be higher than currently
recognised, particularly in the paediatric population.
The prevalence of TINU is higher in younger age groups and there is a female preponderance although this gender
effect appears weaker than suggested by early studies. Although important genetic contributions have been proposed,
the small size of studies and variation between reports currently preclude identification of a ‘pro-TINU’ haplotype. Drugs
and infections have been proposed as the leading acquired risk factors for the development of TINU; whilst the small
size of TINU cohorts and issues of study design limit interpretation of many studies. Larger datasets from the renal
literature suggest that the majority of these cases are precipitated by a drug-induced hypersensitivity reaction; however
in many ophthalmic cases no clear precipitant is identified.
Keywords: Tubulointerstitial nephritis and uveitis syndrome, TINU, Tubulointerstitial nephritis, Uveitis, Inflammation
Background
Tubulointerstitial nephritis and uveitis (TINU) syn-
drome was first described in 1975 by Dobrin et al. [1]. A
comprehensive review published in 2001 identified 133
cases in the world literature and proposed diagnostic cri-
teria for this entity [2]. It is defined as the occurrence of
tubulointerstitial nephritis (TIN) and uveitis in a patient
in the absence of other systemic diseases that can cause
either interstitial nephritis or uveitis; it is therefore a
diagnosis of exclusion [2, 3]. TINU is thought to be an
immune mediated process that may be precipitated by
drugs or infections, although in many cases no cause is
identified (idiopathic) [2]. Most series suggest that TINU
only accounts for 0.1–2% of patients seen in specialized
uveitis centres but the syndrome is likely to be under-
diagnosed [2, 4]. Given that over half of all uveitis cases
have no identified cause it is pertinent to consider TINU
in undifferentiated cases of uveitis, and to be aware of its
possible associations with common systemic medications
and infections. The challenge of diagnosis is in part com-
pounded by the heterogeneity that exists within the uveitis
spectrum. Although all forms of uveitis are characterised
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by intraocular inflammation, the symptoms and signs seen
vary according to the primary site of inflammation within
the eye (the anatomical subtype of uveitis). Most patients
with TINU experience a bilateral sudden-onset anterior
uveitis which presents with typical symptoms of redness,
pain and photophobia. It is becoming clear, however, that
this is not the only uveitic phenotype associated with
TINU and that ophthalmologists need to remain alert to
the possibility of TINU in the context of other clinical pre-
sentations of uveitis.
TIN itself is a potentially life-threatening condition,
accounting for up to 15% of cases of acute kidney injury
(AKI) and is characterised histologically by interstitial
oedema with inflammatory cell infiltrates and tubular
damage [5]. TIN should be considered in the differential
diagnosis of all patients with unexplained AKI or pro-
gressive reduction in glomerular filtration rate (GFR).
The urine sediment may be bland or active (denoted by
the presence of red cells and red cell casts). Tubular pro-
teinuria may be detectable but high levels of albuminuria
are usually absent because glomerular pathology is not
prominent. A proportion of patients with acute interstitial
nephritis (AIN) exhibit sterile pyuria. Patients may present
with non-specific constitutional symptoms including fever,
rash, joint pain, malaise or flank tenderness or be asymp-
tomatic and detected through abnormal renal function
(estimated GFR) tests. A proportion of patients develop
peripheral blood eosinophilia but this is in an inconsistent
feature. Similarly, urinary eosinophilia may be detectable
in some patients but this abnormality is not evaluated in
routine laboratory tests at most centres. A renal biopsy is
required to confirm the diagnosis. It is also important to
exclude systemic diseases known to cause a similar over-
lap of ocular and renal inflammation, notably sarcoidosis,
Sjogren’s syndrome, systemic lupus erythematosus (SLE),
and tuberculosis (TB).
In this review we consider the available evidence re-
garding the epidemiology of this rare condition, and crit-
ically appraise the evidence underlying the current
understanding of both genetic and environmental risk
factors. Furthermore, it is recognised that the challenges
faced in assessing incidence and prevalence in TINU are
replicated across many other rare diseases, including
many sight-threatening forms of uveitis (such as bird-
shot chorioretinopathy and punctate inner choroidopa-
thy). A critical and systematic approach to the evidence
around all such rare uveitis syndromes is needed, both
to clarify what is known but also to highlight areas
where there is currently a major evidence gap.
Methods (search strategy)
The original literature search was undertaken in January
2016, with an updated search conducted in May 2016 to
identify any ‘late-breaking’ articles. The following databases
were searched: Medline, EMBASE, and the Cochrane Li-
brary with a date limit of 1946 to the present for Medline,
1974 to present for EMBASE and no date restriction for
Cochrane. The search used the following terms: “Tubu-
lointersititial nephritis and uveitis”, “TINU syndrome” and
related terms resulting in 498 identified articles; 252 arti-
cles were excluded on the basis of being duplicates (225)
or not directly relevant (27). In order to provide greater in-
formation on the lower end estimates of prevalence and in-
cidence of TINU it was important to include studies that
described large cohorts of uveitis patients in whom no
cases of TINU were reported. To achieve this additional
searches were undertaken using the terms: “Uveitis” and
“prevalence OR incidence” with identification of studies
containing more than 500 patients (250 for paediatric co-
horts), and supported by hand-searching of the bibliog-
raphies of relevant studies.
All relevant clinical studies were considered but were
weighted according to their level of evidence, in which
well-designed randomized prospective clinical trials
would be ranked highest and case-reports ranked lowest
(excluding expert opinion); case-reports were generally
excluded from the final review unless they were consid-
ered to provide unique insights not evident from higher
level studies. Articles which did not present primary data
(such as reviews and expert opinion) were also consid-
ered and were included if they provided original insights
into the condition, based on appropriate published pri-
mary data. In addition their bibliographies were hand-
searched to identify any relevant additional articles.
There were no language restrictions on this review.
Epidemiology
Global estimates of prevalence
TINU is a rare condition, and estimates of its prevalence
within patients attending specialist uveitis services range
from <0.1% to 2% in ‘all age’ populations and up to 2.3%
in paediatric populations (Table 1). Nevertheless, the
data is limited and does not allow more accurate esti-
mates. Of the larger surveys of ‘all age’ uveitis services,
the highest estimates come from Oregon (USA) where
in 1988 Rosenbaum reported five patients with bilateral
anterior uveitis and renal disease (three of whom had
histologically confirmed interstitial nephritis) [3], and re-
ported that TINU was diagnosed in 1.7% of uveitis pa-
tients attending his clinic [6]. Interestingly almost two
decades later Mackensen et al. reported on TINU in the
same uveitis service over the period 1985–2005 and
again found a prevalence of 1.7%, representing 33 of
1985 patients [7]. The 2009 multicentre epidemiological
survey in Japan noted a prevalence of 0.4% (n = 15)
in 3830 patients with uveitis attending specialist uve-
itis services [8]. In Manchester (UK) Jones reported a
prevalence of 0.2% (n = 7) in 3000 uveitis cases seen
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between 1991 and 2013 [9]. The UK cohort from
Jones et al. is of particular interest as it also provides
an estimate of overall incidence for referral to their
uveitis service, allowing an estimate of the incidence
of diagnosed TINU as around 1 per 10 million popu-
lation per year for their region of the UK [9]. Most
series that report any cases of TINU, report preva-
lence between 0.2–0.6% [8–12]. However there are a
number of large surveys that report no cases of TINU
(equating to a prevalence within their uveitis services
of <0.1%).
This variation between series may come from a num-
ber of factors which we classify as: true differences be-
tween the population (genetic and/or environmental):
true differences between the samples arising from the na-
ture of the uveitis service (paediatric, adult or both;
secondary or tertiary; state or private); or measurement
differences between the samples (diagnostic criteria used;
the degree of missed diagnosis; design of the study); or
reporting differences between the samples (ie cases are di-
agnosed but are simply labelled as ‘other’ in reports of
uveitis prevalence). Although there does appear to be a
true difference in prevalence between certain popula-
tions which may be linked to genetic susceptibility (dis-
cussed later), much of the discordance between series
may also arise from the influence of these other factors
as outlined below. Recognition of these factors are im-
portant as they will affect any estimates of global preva-
lence: unrestricted aggregation of all series in Table 1
would suggest a prevalence of 0.2% in ‘all age’ uveitis
services whereas this rises to 0.6% if only those studies
that reported at least one TINU case are included.
Table 1 Studies since 1990 reporting on distribution of uveitis types
Author Data range Country Design TINU cases/ population(n) TINU cases (%)
‘All-age’ Studies with >500 patients
Rodriguez [47] 1982–1992 USA Retrospective 0/1237 0
Rothova [48] 1984–1989 The Netherlands Retrospective 0/865 0
Mackensen [7]* 1985–2005 USA Retrospective 33/1985 1.66
Mercanti [49] 1986–1993 Italy Retrospective 0/655 0
Oruc [50] 1990–1995 USA Retrospective 0/853 0
Tran [51] 1990–1993 Switzerland Prospective 0/558 0
Jones [9] 1991–2013 UK Prospective 7/3000 0.23
Kotake [52] 1994 Japan Retrospective 4/551 0.73
Barisani-Asenbauer [53] 1995–2009 Austria Retrospective 0/2619 0
Rathinam [54] 1996–2001 India Retrospective 0/8759 0
Singh [55] 1996–2001 India Retrospective 0/1233 0
Yang [56] 1996–2003 China Retrospective 0/1752 0
Soheilian [57] 1997–2000 Iran Retrospective 0/544 0
Jakob [12] 2001–2006 Germany Retrospective 10/1916 0.52
Al Dhibi [58] 2001–2010 Saudi Arabia Retrospective 0/888 0
Kazokoglu [59] 2004 Turkey Prospective 0/761 0
Ohguro [8] 2009–2010 Japan Prospective 15/3830 0.39
Gonzalez Fernandez [60] 2012–2013 Brazil Prospective 0/1053 0
Total 69/33059 0.21
Paediatric Studies with >250 patients
Smith [61] 1980–2005 USA Retrospective 12/527 2.28
Kump [4] 1985–2003 USA Retrospective 3/269 1.12
BenEzra [62] 1989–1999 Israel Retrospective 4/275 1.45
Paroli [63] 1995–2004 Italy Retrospective 4/257 1.55
Total 23/1328 1.73
For inclusion a minimum number of 500 was required for ‘all age’ cohorts and a minimum number of 250 patients for paediatric cohorts. As discussed in the text,
it should be recognised that studies which report 0 cases of TINU may do so due to (1) a true rarity in that population, (2) non-reporting of diagnosed cases
(eg studies marked with a ‘+’ include the listing of ‘other diagnoses’ which could potentially include TINU cases), or (3) underdiagnosis
*Includes ‘possible’ as well as ‘probable’ and ‘definite’ cases
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Impact of missed diagnoses on estimates of prevalence of
TINU
Although originally described in 1975 [1], TINU has re-
ceived much greater attention from the late 1980s. It is
likely therefore that more recent series e.g. from the
1990s onwards provide more accurate prevalence fig-
ures, although clearly expertise in this area was present
in certain centres much earlier [3, 6]. Since patients with
TIN may be asymptomatic or exhibit nonspecific symp-
toms (fever, abdominal pain) that do not lead to kidney
function tests being performed, diagnosis of TINU may
be significantly delayed or still unrecognized even after
the onset of uveitis symptoms and ophthalmological as-
sessment [13, 14]. Even when both the uveitis and renal
disease are symptomatic, they may not be synchronous
and so the connection between them may be missed. The
review by Mandeville noted that ocular symptoms were
concurrent with systemic symptoms in only 15% cases; in
21% cases uveitis occurred before systemic symptoms, oc-
curring up to two months beforehand; in 65% cases, uve-
itis occurred after systemic symptoms with a median of
3 months, but noted up to 14 months [2].
It is often suggested that TINU is under-recognised
and that most incidence and prevalence figures are likely
to be under-estimates. The study from Mackensen et al.
provides data to support this [7]. They identified that in
the cohort of 1985 patients, 26 had been diagnosed with
TINU during routine care (prevalence of 1.3%) however
a further 7 patients who had been labelled idiopathic
were consistent with TINU based on the criteria of typ-
ical bilateral sudden onset anterior uveitis with renal
dysfunction (total prevalence of 1.7%) [7]. They also
identified that there were a further 18 ‘idiopathic’ paedi-
atric cases in which the uveitis was typical but in whom
there had not been adequate laboratory investigations to
rule in or rule out the diagnosis, leading to the possibil-
ity that the real prevalence is even higher [7].
Much of the previous discussion considers the identifi-
cation of TINU cases from the ophthalmic perspective
i.e. in a cohort of patients with established uveitis, how
many have TINU? Equally important is to consider the
renal perspective: in a cohort of patients with AIN, how
many have associated uveitis? ‘Missed’ diagnoses may
arise due to a failure of ‘diagnosis’ or a failure of ‘con-
nection’. Just as studies show that even where concur-
rent renal disease has been diagnosed it may not have
been appreciated by the ophthalmologist [7], so it is
likely that there may be cases of AIN in which uveitis is
either not diagnosed or is diagnosed but not connected
(the patient does not deem the concurrence relevant so
that the renal physician and ophthalmologist may not
become aware of the other condition). One potential
concern is whether uveitis may be missed because it is
asymptomatic. In a retrospective review of 26 children
with biopsy-proven TIN in Finland, uveitis was diag-
nosed in 12/26 (46%); uveitis was asymptomatic in 7/12
(58%) [15]. Interestingly, when a prospective study was
conducted in the same population with regular slit-lamp
examination (at onset of TIN, and at 3 and 6 months
afterwards), a remarkable 16/19 (84%) were found to
have uveitis; in 9/16 this was either diagnosed as part of
the baseline examination or had already been diagnosed
within the preceding month [16]. It is not clear whether
these very high rates are specific to this young Finnish
population, or whether there are indeed high rates of
asymptomatic uveitis that go unnoticed and undiagnosed
in the TIN population.
Impact of diagnostic certainty on estimates of prevalence of
TINU
In addition to highlighting ‘missed cases’, the Mackensen
study also illustrates how the level of diagnostic certainty
required will impact the reported prevalence [7]. The
study explicitly includes 13 possible and 7 probable cases,
as well as 13 definite cases (classified according to the
modified criteria of Mandeville et al. which are discussed
later [2]), so providing a maximal prevalence in that co-
hort. It is worth noting that if only the definite cases were
included then the prevalence within this service would
have been 0.65%, more similar to other series.
Demographic factors
Younger age as a risk factor for TINU
The age group studied will also significantly affect the
reported prevalence. TINU is predominantly seen in
younger patients. In the review by Mandeville et al. of
133 patients gathered from the world literature, they
identified a median age of onset of 15 years with a range
of 9–74 years [2]. This was very similar to the results of
the largest single series in which Mackensen et al. re-
ported a median (range) of 15 (6–64) years of age [7].
Indeed TINU may be a relatively common entity in the
paediatric population. In a study from Japan, Goda et al.
reported that TINU was the second most common diag-
nosis in children with uveitis [17]. Similarly it can be de-
rived from the Mackensen data that TINU was nearly
seven-fold more common as a cause of sudden onset bi-
lateral anterior uveitis in those under the age of 20 than
in those above that age; indeed they estimated that 32%
of those with the typical uveitis in the younger age group
had TINU of which around half were in the ‘definite’ or
‘probable’ categories [7]. It is also worth noting that
studies that are based on renal ‘case-finding’ (i.e. that
look at the rates of TINU as a subset of all those with
biopsy-proven TIN), consistently report higher rates of
TINU in children with TIN rather than adults with TIN.
For example Li et al., studying a Chinese cohort, found
that 31/112 (28%) adults with TIN developed uveitis
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[18], whereas in their series Perasaari et al. reported that
20/31 (65%) children with TIN developed uveitis [19].
Female gender may be a risk factor for TINU
There may also be a gender bias in TINU. Although
Mandeville reported a 74% (n = 98/133) female prepon-
derance they noted that the proportion of male patients
being reported was increasing over time. Most series,
even recent ones, continue to report a female bias, al-
though the Mackensen study found that 60% of their 33
cases were male. It is also suggested that gender may
affect age of onset. Mandeville et al. reported a median
age of onset of 14 years in males versus 17 years in fe-
males [2], and Mackensen et al. a median age of onset of
15 years in males versus 40 years in females [7].
Ethnicity does not appear to be a risk factor for TINU
TINU syndrome has not yet been shown to have racial
predilection with cases reported across most ethnic
groups, and being reported to be present (at 0.2% or
higher) in specialist uveitis services across the world in-
cluding the USA, UK, Germany, Italy, Israel, Japan and
Thailand [2]. The possibility of genetic susceptibility is
discussed separately below.
Genetic and environmental factors
Genetic susceptibility as a risk factor for TINU
Evidence of a genetic predisposition comes from familial
clustering and human leucocyte antigens (HLA)-suscep-
tibility studies [19]. Clinical reports include monozygotic
twins, siblings and a case of a mother and son diagnosed
with TINU several years apart [19–23]; there is also one
report of monozygotic twins who both developed inter-
stitial nephritis but with uveitis only occurring in one of
them [24].
Several studies have reported on specific HLA associa-
tions with TINU syndrome [19, 25–30] but all studies are
limited in size and there is significant variation between
studies that may reflect the populations sampled. In
addition, many earlier reports are based on serological tech-
niques that restricts comparison to later studies [21, 27].
Based on early reports Mandeville et al. suggested that
HLA-A2 and -A24 were important antigens associated
with this disorder in Japanese subjects, because these 2
antigens had been identified in a majority of Japanese
patients with TINU (75%) however both of these speci-
ficities are common in the Japanese population [2]. In-
deed Matsumoto et al. reported that whereas HLA-A2
and –A24 were present in 32% and 55% of 22 Japanese
patients with biopsy proven TINU, this compared to
48% and 64% of 50 healthy Japanese controls [30].
In 2003 Levinson reported on a significant multicenter
study of 18 patients with TINU from the USA in which
they found that TINU was associated with HLA-
DQA1*01, HLA-DQB1*05 and HLA-DRB1*01 with rela-
tive risks (RR) of 19.5, 16.3 and 25.5 respectively, and a
weaker association with HLA-B14 (RR = 8.5) [25]; cau-
tion is needed in interpreting the relative contributions
of each of these ‘risk’ alleles due to linkage disequilib-
rium. The strongest association was with the HLA-
DRB1*0102 allele (a subtype of HLA-DRB1*01) which
they reported to be present in 13/18 (72%) of TINU pa-
tients vs 1.6% of the control population leading to an es-
timated RR of 167.1; the control rates were based on
published rates in North American whites based on 17/
18 of the series being of this genetic background. In fact
it appears that this allele was only present in 12/18 of
that cohort, leading the group to subsequently revise the
relative risk of that allele to 46.3 [26].
In a later study Mackensen et al. compared the allelic
frequencies noted in this original study, with two clinic-
ally relevant cohorts: (1) patients with sudden-onset, an-
terior bilateral uveitis but without TIN (n = 28); and (2)
patients with TIN but without uveitis (n = 14) [26]. It
should be noted that these two comparator groups were
conducted in a European population (and the control
rates were also based on published European allelic fre-
quencies), but it is striking that the HLA-DRB1*0102 al-
lele was associated with the uveitis cohort (RR = 14.3)
but not in those with tubulointerstitial nephritis without
uveitis; this uveitis cohort was also associated with
HLA-DRB1*08 (RR = 4.0), an allele which had not been
found to be associated with the original TINU cohort
(n = 1/18). Interestingly Reddy et al. reported that 14/15
paediatric patients with unexplained panuveitis had a
HLA-DRB1*01-HLADQB1*05 haplotype (identified as
being high risk for TINU in the Levinson study) but did
not have any evidence of interstitial nephritis, again rais-
ing the possibility that some of these alleles are risk fac-
tors for uveitis rather than specifically for TINU [29].
In Finland Perasaari et al. conducted a population
based study that identified 31 paediatric patients with
biopsy-proven TIN, in whom 20 patients were identified
as having TINU [19]. This reported a series of novel
HLA-associations but did not detect associations with
the previously reported ‘TINU susceptibility’ alleles iden-
tified by Levinson. The previously identified ‘high risk’
HLA-DRB1*0102 allele is very rare in the Finnish popu-
lation, and neither it nor any other HLA-DRB1*01 allele
was found to be associated with TINU in this cohort.
The susceptibility alleles in the Finnish cohort were
HLA-DQA1*04:01 (RR = 4.0), HLA-DQA1*01:04
(RR = 6.1), HLA-DRB1*08 (RR = 3.0), and HLA-
DRB1*14 (RR = 8.2) [19]. The association between TINU
and HLA-DRB1*08 is interesting since, as noted earlier,
Mackensen had previously found this to be associated
with sudden-onset, anterior bilateral uveitis in the ab-
sence of TIN and not associated with TINU itself [26].
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Numerous other case reports and small case series
have been published in which selected haplotype data is
presented [27] but provide little additional contribution
to our overall understanding of genetic susceptibility in
TINU. All studies vary in their study design, case-
finding and population sampled, and there is as yet no
consistent evidence to define a susceptibility genotype
across populations.
Drugs as a risk factor for TINU
Two major acquired risk factors have been proposed for
TINU: drugs and infections. The main drug groups that
have been implicated are non-steroidal anti-inflammatory
agents and antibiotics [31–35]. Caution should be exer-
cised when evaluating studies that report associations be-
tween these environmental risk factors and the onset of
TINU. A number of factors should be borne in mind: (1)
most of the studies in this area are retrospective and are
subject to recall bias; (2) the proposed risk factors are very
common in the general population and yet most studies
do not have a control group to provide any comparator
for this; (3) the risk factors may co-exist causing difficul-
ties in assessing their relative contributions (e.g. a patient
who develops TINU after an infection which has been
treated with antibiotics with symptom relief by NSAIDs);
(4) the risk factors for TINU may not be identical to the
risk factors for TIN without uveitis. The following studies
should be considered within this context.
In their 2001 review, Mandeville et al. noted that
evaluation of potential risk factors for TINU had been
considered for 122 of 133 cases, with positive identifica-
tion of risk factors in 63 [2]. Antibiotic usage was the
commonest reported risk factor (29/122), with NSAIDs
the next most common (22/122). In their series of 33 pa-
tients with TINU, Mackensen et al. reported that 9/33
had been taking NSAIDs (7/9 were ibuprofen), and 2/33
had been taking antibiotics prior to disease onset; how-
ever they concluded that there were no cases of definite
drug-induced TINU [7]. In a series of 31 patients from
China, Li et al. reported that prior drug usage was iden-
tified in 20/31 cases comprising antibiotics (6/31),
NSAIDs (1/31), Chinese herbs (1/31) or a combination
of drugs (12/31) [18]. In the series of 31 patients from
Finland, Perasaari et al. reported 19/31 patients had re-
ceived antibiotics or non-steroidal anti-inflammatory
drugs (NSAIDs) or both, within the two months prior to
diagnosis [19].
TIN cohort studies with few or no cases of reported
co-existing uveitis, typically comprise older patients and
feature a majority (60–70%) postulated to be drug-
induced [35, 36], with antibiotics, proton pump inhibi-
tors (PPI) and NSAIDs being the commonest proposed
casual agents. Most drug-induced TIN is thought to be a
hypersensitivity reaction rather than direct toxicity [35].
Notably, unlike antibiotics and NSAIDs, PPIs have not
been linked to TINU, perhaps suggesting distinct patho-
genic mechanisms for ocular and renal injury among
these different drug classes.
It is interesting that the drugs most commonly re-
ported as a potential precipitant for TIN or TINU are
not those for which there is strong evidence of causing
isolated drug-induced uveitis. Moorthy et al. reviewed
causes of isolated (non-TINU) drug-induced uveitis,
using the well-established Naranjo’s criteria to assess
likelihood of causality between drugs and adverse reac-
tions [37, 38] Their list of drugs for which there is a ‘def-
inite’ association with inducing uveitis include cidofovir,
rifabutin, sulfonamides, bisphosphonates, and both in-
traocular and topical therapies, but does not include
those drugs typically reported in either TIN or TINU.
This would suggest that the mechanism of induction of
uveitis in the context of TINU may be distinct from
other forms of drug-induced uveitis.
Infection as a risk factor for TINU
In general, infection is thought to be a much less com-
mon cause of acute TIN than drug-induced disease. A
number of case reports have linked TIN to viral infec-
tions including hantavirus, cytomegalovirus, Epstein-
Barr virus (EBV), polyoma (BK) virus, adenovirus and
HIV. In HIV infection, TIN is normally coexistent with
glomerular disease. Tuberculosis is an important cause
of TIN that typically exhibits a granulomatous appear-
ance. Mycobacteria cannot usually be identified in renal
biopsy by Ziehl-Neelsen staining and empirical treat-
ment may be required after early morning urine cultures
have been collected. Granulomatous TIN may also arise
from non-infective causes, specifically drug-induced TIN
and sarcoidosis. Legionella and histoplasmosis have also
been reported to cause TIN but in the main, bacterial
and fungal infection is rarely associated with acute TIN.
With regard to TINU, Mandeville et al. noted that in-
fections had been reported in a number of patients, most
commonly respiratory tract infections (15 of the 122 for
which risk factors had been considered); other sites re-
ported were gastrointestinal, kidney, and other genito-
urinary sites [2].
Specific infective agents reported as being possibly asso-
ciated with TINU include tuberculosis [39, 40] systemic
toxoplasmosis [41], EBV [42–44] and varicella zoster re-
activation [45]. The evidence for the aetiological link here
is very variable. In the cases reporting tuberculosis-
associated TINU, the Mycobacterium tuberculosis does in-
deed appear to be causative although it is arguable
whether these should be classified as TINU given the ex-
clusions regarding underlying systemic disease proposed
by Mandeville et al. [2]. In most of the viral-associated
TINU the link is much less certain, and may simply be
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based on the presence of positive serology, such as IgG for
EBV, that occurs at a high prevalence in the background
population [44]. Most TINU studies do not specifically
comment on the presence of preceding infection. Some
estimate may be inferred from the frequency of prior anti-
biotic usage, such as in the studies by Mackensen et
al., Li et al. and Perasaari et al. [7, 18, 19].
Other risk factors for TINU
Various studies have noted the coexistence of other sys-
temic diseases, notably rheumatoid arthritis, hyperthy-
roidism and parathyroidism; it is possible that they are
linked in individual cases due to shared inappropriate
immune responses, but it is equally possible that these
are coincidental occurrences [2].
The focus of this review on TINU is is on the epi-
demiological aspects of TINU rather than its pathogen-
esis, however it should be noted that the increased
understanding of one can inform the other: identifica-
tion of risk factors for TINU through epidemiological
studies may help inform our understanding of its patho-
genesis; conversely elucidation of the pathogenesis of
TINU through basic science studies may improve our
understanding of which of the putative risk factors are
relevant and how they interact. In this regard the pro-
posal by Tan et al. that modified C-reactive peptide may
be a target auto-antigen in TINU is of particular interest
[46]. Although it needs to be further explored, it can be
readily seen how such hypotheses of a final common
autoimmune pathway provides an explanation of how
different environmental triggers might cause genetically
susceptible individuals to develop TINU.
Conclusion
In this systematic epidemiological review of TINU we
have critically appraised current estimates of the incidence
and prevalence of this rare disease, and to highlight some
of the reasons that different studies can lead to widely dif-
fering estimates of these measures. It should be noted that
the challenges faced in studying the epidemiology of
TINU are common to many other rare diseases. As sys-
tematic reporting through national or international regis-
tries becomes more common, these estimates for TINU
and other rare syndromes should become more precise,
although it should also be recognized that there also needs
to be consensus around disease definitions and what con-
stitutes the inclusion criteria for registration. This is par-
ticularly challenging for syndromes which are primarily
based on clinical phenotype (such as most of the uveitic
syndromes) rather than those which can be confirmed on
the basis of a distinct genotype or have some other sensi-
tive diagnostic test.
We have also used the epidemiological data and the
key cohorts identified to consider the risk factors for
TINU and how this enables identification of susceptible
populations. In such populations (notably in the young
with sudden onset bilateral uveitis), it may be relatively
common. It is proposed that there is a genetic suscepti-
bility, although it remains unclear the extent to which
this is specific to TINU or to uveitis in general, and
studies have been somewhat variable in their findings
across populations, probably reflecting the relatively
small size of even the largest TINU studies. Although a
full discussion of the pathogenesis of TINU is beyond
the scope of this article, it is relevant to note here that a
theory of pathogenesis needs to evaluate and then ac-
count for those risk factors that are significantly associ-
ated with development of the disease. The current
proposal is that TINU arises from an interaction of an
environmental trigger (such as a drug or rarely an infec-
tion) with a susceptible genetic background, and that
this triggers an autoimmune cascade. This will be dis-
cussed in our companion review (manuscript in prepar-
ation), but it should be recognized that the process is
very poorly understood, and requires further investiga-
tion. Our epidemiological and descriptive studies that
identify ‘association’ must be complemented by im-
munological studies that can elucidate ‘causation’. In this
way we will be able to identify the individuals who are at
risk, improve diagnosis within these populations, and
translate better understanding of disease to improve our
care of these vulnerable patients.
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